Table 3.
Stage of liver disease and performance status at the time of HCC diagnosis according to disease etiology
| Overall cohort | MASLD | Non‐MASLD | P value | |
|---|---|---|---|---|
| Stage of liver disease at the time of HCC diagnosis | ||||
| Cirrhosis, n (%) | 530 (77.1) | 113 (64.2) | 417 (81.6) | < 0.001 |
| Ascites, n (%) | 177 (25.8) | 39 (22.2) | 138 (27.0) | 0.200 |
| Ascitic status unknown | 1 (0.1) | 0 (0.0) | 1 (0.2) | |
| Hepatic encephalopathy, n (%) | 32 (4.7) | 5 (2.9) | 27 (5.3) | 0.173 |
| Hepatic encephalopathy unknown | 16 (2.3) | 2 (1.1) | 14 (2.7) | |
| MELD‐Na score in people with cirrhosis | ||||
| MELD‐Na score, median (IQR) | 9.8 (6.8) | 9.5 (5.9) | 9.8 (7.0) | 0.815 |
| MELD‐Na score ≤ 6, n (%) | 76 (14.3) | 16 (14.2) | 60 (14.4) | 0.919 |
| MELD‐Na score < 9, n (%) | 253 (47.7) | 54 (47.8) | 119 (47.7) | 0.934 |
| MELD‐Na score unknown | 9 (1.7) | 1 (0.6) | 8 (1.9) | |
| ECOG performance status | ||||
| 0, n (%) | 436 (63.5) | 109 (62.0) | 327 (64.0) | 0.872 |
| 1, n (%) | 74 (10.8) | 18 (10.2) | 56 (11.0) | 0.855 |
| 2, n (%) | 86 (12.5) | 23 (13.1) | 63 (12.3) | 0.722 |
| 3, n (%) | 40 (5.8) | 11 (6.3) | 29 (5.7) | 0.729 |
| 4, n (%) | 15 (2.2) | 3 (1.7) | 12 (2.3) | 0.639 |
| ECOG performance status unknown | 36 (5.2) | 12 (6.8) | 24 (4.7) | |
| ALBI grade | ||||
| Grade 1, n (%) | 279 (40.6) | 86 (48.9) | 193 (37.8) | 0.010 |
| Grade 2, n (%) | 317 (46.1) | 74 (42.0) | 243 (47.6) | 0.206 |
| Grade 3, n (%) | 83 (12.1) | 16 (9.1) | 67 (13.1) | 0.158 |
| ALBI grade unknown | 8 (1.2) | 0 (0.0) | 8 (1.6) | |
ALBI grade, albumin–bilirubin grade; ECOG performance status, Eastern Cooperative Oncology Group performance status; HCC, hepatocellular carcinoma; MASLD, metabolic dysfunction‐associated steatotic liver disease; MELD, model for end‐stage liver disease.